Locations:
Search
Recently launched first-of-kind study aims to address an unmet therapeutic need
Biomarker promises a practical way to reduce misdiagnoses
AHA scientific statement offers best practices to improve care for high-risk populations
Relapse rates were lower with oral or infusion therapy after initial injectable DMT
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
No notable difference in reactions with two-hour infusion in ENSEMBLE PLUS substudy
We now have an expanded toolbox to extend survival and lessen treatment toxicity
Registry-based study is first to assess the issue in relation to cognition in epilepsy
Insights on leveraging collaboration and advocacy to develop and conduct needed trials
High plasma ApoA1 and TG/HDL-C ratio predict faster progression
Findings suggest new ways to improve outcomes
Advertisement
Advertisement